PRGO:NYE-Perrigo Company plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 24.64

Change

0.00 (0.00)%

Market Cap

USD 12.59B

Volume

1.63M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
PRGO VTI
  • VTI
Relative Returns (From:    To: 2025-04-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.82 (-1.22%)

USD 66.32B
HLN Haleon plc

-0.03 (-0.29%)

USD 45.41B
TAK Takeda Pharmaceutical Co Ltd A..

+0.22 (+1.50%)

USD 43.84B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.39B
ELAN Elanco Animal Health

+0.04 (+0.47%)

USD 4.28B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.23 (-3.13%)

USD 3.25B
BHC Bausch Health Companies Inc

-0.38 (-7.45%)

USD 1.60B
CPHI China Pharma Holdings Inc

N/A

USD 4.61M
YCBD cbdMD Inc

N/A

USD 1.44M
EBS Emergent Biosolutions Inc

-0.08 (-1.73%)

N/A

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
XMET:AU BetaShares Energy Transit.. 4.93 % 0.00 %

N/A

N/A
LIMI Themes Lithium & Battery .. 3.86 % 0.00 %

+0.21 (+1.03%)

USD 0.49M
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.11 (1.03%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

-0.39 (1.03%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

-0.45 (1.03%)

CAD 0.81B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 0.00 % 0.00 %

-0.11 (1.03%)

CAD 0.02B
BLUM:F 0.00 % 0.00 %

N/A

N/A
ION Proshares S&P Global Core.. 0.00 % 0.00 %

+0.14 (+1.03%)

USD 2.31M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.16% 79% B- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.16% 79% B- 58% F
Trailing 12 Months  
Capital Gain -18.73% 36% F 20% F
Dividend Return 2.73% 50% F 48% F
Total Return -16.00% 36% F 20% F
Trailing 5 Years  
Capital Gain -51.08% 46% F 8% B-
Dividend Return 9.67% 40% F 21% F
Total Return -41.41% 46% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -12.98% 7% C- 5% F
Dividend Return -10.48% 7% C- 5% F
Total Return 2.50% 83% B 56% F
Risk Return Profile  
Volatility (Standard Deviation) 8.06% 100% F 83% B
Risk Adjusted Return -130.09% 7% C- N/A F
Market Capitalization 12.59B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector